| scholarly article | Q13442814 |
| P2093 | author name string | M Noguchi | |
| G Künstle | |||
| J Laine | |||
| T Obata | |||
| M Sha | |||
| P2860 | cites work | A human protein kinase Bgamma with regulatory phosphorylation sites in the activation loop and in the C-terminal hydrophobic domain | Q22009089 |
| Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor | Q22009126 | ||
| AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas | Q24294176 | ||
| Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death | Q24311298 | ||
| Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria | Q24311858 | ||
| AH/PH domain-mediated interaction between Akt molecules and its potential role in Akt regulation | Q24317438 | ||
| Phosphorylation and activation of p70s6k by PDK1 | Q24323433 | ||
| Identification of the TCL1 gene involved in T-cell malignancies | Q24336607 | ||
| The PI3K-PDK1 connection: more than just a road to PKB | Q24531972 | ||
| STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells | Q24534351 | ||
| Identification of a pocket in the PDK1 kinase domain that interacts with PIF and the C-terminal residues of PKA | Q24600810 | ||
| Genomic analysis of human and mouse TCL1 loci reveals a complex of tightly clustered genes | Q24647269 | ||
| Functional cleavage of the common cytokine receptor gamma chain (gammac) by calpain | Q24655060 | ||
| Abnormalities at 14q32.1 in T cell malignancies involve two oncogenes | Q24673023 | ||
| Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase | Q24682825 | ||
| Crystal structure of p14TCL1, an oncogene product involved in T-cell prolymphocytic leukemia, reveals a novel beta-barrel topology | Q27748971 | ||
| Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery | Q27860586 | ||
| Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B | Q28116107 | ||
| Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt | Q28255373 | ||
| The PH domain: a common piece in the structural patchwork of signalling proteins | Q28256159 | ||
| Regulation of cell death protease caspase-9 by phosphorylation | Q28288607 | ||
| Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L) | Q28297419 | ||
| Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate | Q28301966 | ||
| Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site | Q28373472 | ||
| Requirement for activation of the serine-threonine kinase Akt (protein kinase B) in insulin stimulation of protein synthesis but not of glucose transport | Q28577282 | ||
| Cellular survival: a play in three Akts | Q29547806 | ||
| Regulation of neuronal survival by the serine-threonine protein kinase Akt | Q29614185 | ||
| BCL-2 family members and the mitochondria in apoptosis | Q29614427 | ||
| Modular binding domains in signal transduction proteins | Q29617351 | ||
| Phosphoinositide kinases | Q29618047 | ||
| The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase | Q29618387 | ||
| Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily | Q30844287 | ||
| PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2. | Q33860504 | ||
| Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria | Q33959022 | ||
| Deregulated expression of TCL1 causes T cell leukemia in mice | Q36011839 | ||
| Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase | Q36103541 | ||
| The common cytokine receptor gamma chain plays an essential role in regulating lymphoid homeostasis | Q36376720 | ||
| Interleukin 3-dependent survival by the Akt protein kinase | Q36593239 | ||
| Involvement of the pleckstrin homology domain in the insulin-stimulated activation of protein kinase B. | Q40999183 | ||
| PI3K: downstream AKTion blocks apoptosis | Q41351876 | ||
| Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. | Q42991716 | ||
| Flow cytometric analysis of the early phases of apoptosis by cellular and nuclear techniques | Q71307571 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | positive regulation of protein serine/threonine kinase activity | Q14862267 |
| TCL1 family AKT coactivator A | Q21097157 | ||
| AKT serine/threonine kinase 1 | Q21114990 | ||
| AKT serine/threonine kinase 2 | Q21116502 | ||
| Mature T cell proliferation 1 | Q21120061 | ||
| TCL1 family AKT coactivator B | Q21127373 | ||
| Thymoma viral proto-oncogene 1 | Q21498923 | ||
| P304 | page(s) | 395-407 | |
| P577 | publication date | 2000-08-01 | |
| P1433 | published in | Molecular Cell | Q3319468 |
| P1476 | title | The protooncogene TCL1 is an Akt kinase coactivator | |
| P478 | volume | 6 |
| Q73944876 | 1H, 15N and 13C chemical shift assignments of the Pleckstrin Homology domain of the Human Protein Kinase B (PKB/Akt) |
| Q37707596 | A Role for KLF4 in Promoting the Metabolic Shift via TCL1 during Induced Pluripotent Stem Cell Generation. |
| Q37235687 | A role for IRF4 in the development of CLL. |
| Q39791614 | AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K. |
| Q26738706 | Aberrant Promoter Hypomethylation in CLL: Does It Matter for Disease Development? |
| Q42353159 | Absence of TCL1A expression is a useful diagnostic feature in splenic marginal zone lymphoma |
| Q37168329 | Accelerated development of chronic lymphocytic leukemia in New Zealand Black mice expressing a low level of interferon regulatory factor 4. |
| Q35971676 | Activating Akt and the brain's resources to drive cellular survival and prevent inflammatory injury |
| Q34151749 | Akt Contributes to Activation of the TRIF-Dependent Signaling Pathways of TLRs by Interacting with TANK-Binding Kinase 1 |
| Q35445077 | Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer |
| Q35077123 | Akt is TCL-ish: implications for B-cell lymphoma. |
| Q36638520 | Akt mediated phosphorylation of LARP6; critical step in biosynthesis of type I collagen |
| Q24312056 | Akt/PKB interacts with the histone H3 methyltransferase SETDB1 and coordinates to silence gene expression |
| Q28241283 | ArgBP2gamma interacts with Akt and p21-activated kinase-1 and promotes cell survival |
| Q36245513 | Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression |
| Q97534301 | Autophagy as a modulator of cell death machinery |
| Q28282926 | BSTA promotes mTORC2-mediated phosphorylation of Akt1 to suppress expression of FoxC2 and stimulate adipocyte differentiation |
| Q49630908 | Blood Gene Expression Predicts Bronchiolitis Obliterans Syndrome |
| Q41615120 | Chemical Inhibitors and microRNAs (miRNA) Targeting the Mammalian Target of Rapamycin (mTOR) Pathway: Potential for Novel Anticancer Therapeutics |
| Q58792718 | Connexin 43 C-terminus directly inhibits the hyperphosphorylation of Akt/ERK through protein-protein interactions in glioblastoma |
| Q37109227 | Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. |
| Q24679620 | Current status of human chromosome 14 |
| Q38331301 | DNA-PKcs, but not TLR9, is required for activation of Akt by CpG-DNA. |
| Q39815562 | Dephosphorylation and inactivation of Akt/PKB is counteracted by protein kinase CK2 in HEK 293T cells |
| Q64104342 | Differential Proteomics Reveals miR-155 as a Novel Indicator of Liver and Spleen Pathology in the Symptomatic Niemann-Pick Disease, Type C1 Mouse Model |
| Q28215276 | Differential expression of TCL1 during pre-B-cell acute lymphoblastic leukemia progression |
| Q42524332 | Direct identification of tyrosine 474 as a regulatory phosphorylation site for the Akt protein kinase |
| Q24540383 | Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma |
| Q35849088 | Dysregulated TCL1 requires the germinal center and genome instability for mature B-cell transformation |
| Q35784734 | EBNA2 interferes with the germinal center phenotype by downregulating BCL6 and TCL1 in non-Hodgkin's lymphoma cells |
| Q30165322 | Equilibrium and pressure-jump relaxation studies of the conformational transitions of P13MTCP1. |
| Q36426727 | Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia |
| Q54976940 | Functional characterization of lysosomal interaction of Akt with VRK2. |
| Q33602001 | GT1b-induced neurotoxicity is mediated by the Akt/GSK-3/tau signaling pathway but not caspase-3 in mesencephalic dopaminergic neurons |
| Q40402226 | Genetic characterization of T-PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker |
| Q91362827 | Genetic predisposition to mosaic Y chromosome loss in blood |
| Q38873932 | Genetic variants associated with mosaic Y chromosome loss highlight cell cycle genes and overlap with cancer susceptibility |
| Q36115671 | Genetics and molecular biology of chronic lymphocytic leukemia |
| Q93012189 | HSP90A inhibition promotes anti-tumor immunity by reversing multi-modal resistance and stem-like property of immune-refractory tumors |
| Q36529496 | Heat shock protein 70 regulates Tcl1 expression in leukemia and lymphomas |
| Q36384635 | High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia |
| Q37427988 | High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia |
| Q30811594 | Identification of Akt association and oligomerization domains of the Akt kinase coactivator TCL1 |
| Q38334984 | Identification of MEF2-regulated genes during muscle differentiation |
| Q34546650 | Identification of nerve growth factor-responsive element of the TCL1 promoter as a novel negative regulatory element |
| Q34550490 | Identification of small proline-rich repeat protein 3 as a novel atheroprotective factor that promotes adaptive Akt signaling in vascular smooth muscle cells |
| Q24814629 | Identification, characterization and metagenome analysis of oocyte-specific genes organized in clusters in the mouse genome |
| Q30985619 | Immune response in silico (IRIS): immune-specific genes identified from a compendium of microarray expression data. |
| Q43815919 | In vitro and in vivo effectiveness of arsenic trioxide against murine T-cell prolymphocytic leukaemia |
| Q37319074 | Inherited predisposition to chronic lymphocytic leukemia |
| Q40508864 | Inhibition of Akt kinase activity by a peptide spanning the betaA strand of the proto-oncogene TCL1. |
| Q38996766 | Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival |
| Q48375750 | Integrated Cellular and Plasma Proteomics of Contrasting B-cell Cancers Reveals Common, Unique and Systemic Signatures |
| Q42078419 | Interaction between TCL1 and Epac1 in the activation of Akt kinases in plasma membranes and nuclei of 8-CPT-2-O-Me-cAMP-stimulated macrophages |
| Q41774347 | Interaction of human biliverdin reductase with Akt/protein kinase B and phosphatidylinositol-dependent kinase 1 regulates glycogen synthase kinase 3 activity: a novel mechanism of Akt activation |
| Q51025796 | Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients' individual gene expression in peripheral blood. |
| Q39041030 | Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133+ cancer stem-like cells in ovarian cancer |
| Q35823730 | Interplay between HIV-1 infection and host microRNAs |
| Q40642733 | JNK-interacting protein 1 promotes Akt1 activation. |
| Q99557461 | LAMP3 induces apoptosis and autoantigen release in Sjögren's syndrome patients |
| Q99586011 | Long-term expansion with germline potential of human primordial germ cell-like cells in vitro |
| Q27302379 | Lysosomal interaction of Akt with Phafin2: a critical step in the induction of autophagy |
| Q92540366 | Machine learning applied to whole-blood RNA-sequencing data uncovers distinct subsets of patients with systemic lupus erythematosus |
| Q33917087 | Maternal effect genes: Findings and effects on mouse embryo development |
| Q38598546 | Mature T-cell leukemias: Molecular and Clinical Aspects. |
| Q64892721 | Mechanisms of the Metabolic Shift during Somatic Cell Reprogramming. |
| Q95273444 | Metabolic remodeling during somatic cell reprogramming to induced pluripotent stem cells: involvement of hypoxia-inducible factor 1 |
| Q47215137 | MiR-29 silencing modulates the expression of target genes related to proliferation, apoptosis and methylation in Burkitt lymphoma cells |
| Q33293113 | Mice lacking the Obox6 homeobox gene undergo normal early embryonic development and are fertile |
| Q35553338 | MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype |
| Q36602853 | MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies |
| Q37103613 | MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications |
| Q37791680 | Molecular basis of CLL |
| Q28393244 | Mosaic loss of chromosome Y is associated with common variation near TCL1A |
| Q37417132 | New insight into the role of miRNAs in leukemia |
| Q34683488 | New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies |
| Q33882138 | Novel inhibitors of AKT: assessment of a different approach targeting the pleckstrin homology domain |
| Q36321986 | PI-3K and Akt are mediators of AP-1 induction by 5-MCDE in mouse epidermal Cl41 cells |
| Q42467584 | PI3-kinase regulates survival of chronic lymphocytic leukemia B-cells by preventing caspase 8 activation |
| Q28242382 | PIKE (phosphatidylinositol 3-kinase enhancer)-A GTPase stimulates Akt activity and mediates cellular invasion |
| Q34990565 | PKB binding proteins. Getting in on the Akt. |
| Q34389540 | PKB/AKT: functional insights from genetic models |
| Q46129869 | PTEN antagonises Tcl1/hnRNPK-mediated G6PD pre-mRNA splicing which contributes to hepatocarcinogenesis |
| Q39850208 | Pharmacologic interception in T-cell leukemia 1A associated pathways as a treatment rationale for chronic lymphocytic leukemia |
| Q24537693 | Phosphoinositol lipids bind to phosphatidylinositol 3 (PI3)-kinase enhancer GTPase and mediate its stimulatory effect on PI3-kinase and Akt signalings |
| Q40605909 | Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium |
| Q37106689 | Prolymphocytic leukaemia of B- and T-cell subtype: a state-of-the-art paper |
| Q51073086 | Protein kinase B beta/Akt2 plays a specific role in muscle differentiation. |
| Q34666940 | Protein kinase C and AKT/protein kinase B in CD4+ T-lymphocytes: new partners in TCR/CD28 signal integration |
| Q30556645 | Protooncogene TCL1b functions as an Akt kinase co-activator that exhibits oncogenic potency in vivo |
| Q37495234 | ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice |
| Q28580317 | Ras GTPase-activating protein binds to Akt and is required for its activation |
| Q36313167 | Regulation of the Akt kinase by interacting proteins |
| Q39007397 | SUMOylation regulates AKT1 activity. |
| Q46658586 | Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia (B-CLL): comparison of indolent and progressive disease |
| Q27643062 | Solution structure and backbone dynamics of the pleckstrin homology domain of the human protein kinase B (PKB/Akt). Interaction with inositol phosphates |
| Q28214220 | Sp1 transactivation of the TCL1 oncogene |
| Q83770207 | Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia |
| Q47415044 | Structural basis for the co-activation of protein kinase B by T-cell leukemia-1 (TCL1) family proto-oncoproteins. |
| Q57031146 | T Cell Leukemia/Lymphoma 1A is essential for mouse epidermal keratinocytes proliferation promoted by insulin-like growth factor 1 |
| Q24681203 | T cell leukemia I oncogene expression depends on the presence of Epstein-Barr virus in the virus-carrying Burkitt lymphoma lines |
| Q58785721 | T-Cell Leukemia/Lymphoma 1 (TCL1): An Oncogene Regulating Multiple Signaling Pathways |
| Q83215187 | T-cell prolymphocytic leukemia |
| Q51775280 | T-cell prolymphocytic leukemia. |
| Q38291794 | TCL-1, MTCP-1 and TML-1 gene expression profile in non-leukemic clonal proliferations associated with ataxia-telangiectasia |
| Q41192923 | TCL1 expression patterns in Waldenström macroglobulinemia |
| Q41419560 | TCL1 expression predicts overall survival in patients with mantle cell lymphoma. |
| Q40812531 | TCL1 oncogene expression in B cell subsets from lymphoid hyperplasia and distinct classes of B cell lymphoma |
| Q28584959 | TCL1 participates in early embryonic development and is overexpressed in human seminomas |
| Q26773053 | TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia |
| Q35214663 | TCL1: a new drug target in lymphoid and germ-cell malignancies? |
| Q36194235 | TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas |
| Q47607631 | TCL1A interacts with TP63 and enhances the survival of Raji Burkitt lymphoma cell line |
| Q24674168 | TORC2 regulates germinal center repression of the TCL1 oncoprotein to promote B cell development and inhibit transformation |
| Q37018730 | Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. |
| Q31040364 | Tcl1 interacts with Atm and enhances NF-κB activation in hematologic malignancies. |
| Q35787000 | Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL) |
| Q38074176 | Technological overview of iPS induction from human adult somatic cells |
| Q38305561 | Telomerase activity, apoptosis and cell cycle progression in ataxia telangiectasia lymphocytes expressing TCL1. |
| Q36313193 | The Akt/PKB pathway: molecular target for cancer drug discovery |
| Q24294452 | The E3 ligase TTC3 facilitates ubiquitination and degradation of phosphorylated Akt |
| Q37506648 | The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma |
| Q37422388 | The Role of miRNA in Haematological Malignancy. |
| Q36213981 | The TCL1 family of oncoproteins: co-activators of transformation |
| Q90350014 | The TCL1 function revisited focusing on metabolic requirements of stemness |
| Q24300764 | The TCL1 oncoprotein binds the RNase PH domains of the PNPase exoribonuclease without affecting its RNA degrading activity |
| Q33492280 | The TCL1A oncoprotein interacts directly with the NF-kappaB inhibitor IkappaB. |
| Q83238023 | The Tcl1 oncogene defines secondary hair germ cells differentiation at catagen-telogen transition and affects stem-cell marker CD34 expression |
| Q34405519 | The activation of Akt/PKB signaling pathway and cell survival. |
| Q38362950 | The long journey of TCL1 transgenic mice: lessons learned in the last 15 years |
| Q35786347 | The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury |
| Q29547860 | The phosphatidylinositol 3-Kinase AKT pathway in human cancer |
| Q38299311 | The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL. |
| Q28199351 | The role of TCL1 in human T-cell leukemia |
| Q24631438 | Therapeutic Implications of Targeting AKT Signaling in Melanoma |
| Q37594770 | Therapeutic peptides for cancer therapy. Part II - cell cycle inhibitory peptides and apoptosis-inducing peptides |
| Q57285472 | Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia |
| Q35163966 | Unravelling the activation mechanisms of protein kinase B/Akt |
| Q30925087 | Use of RNA interference-mediated gene silencing and adenoviral overexpression to elucidate the roles of AKT/protein kinase B isoforms in insulin actions |
| Q36629387 | Whole-transcriptome analysis of flow-sorted cervical cancer samples reveals that B cell expressed TCL1A is correlated with improved survival. |
| Q38135352 | miR deregulation in CLL. |
Search more.